BioSpace News Archive

Low cost production and superior product purity of the diabetes drug liraglutide with NUMAFERM’s unique technology platform

In the pharmaceutical industry, continuous and secure data acquisition and documentation is crucial for production and storage requirements, and also for research and development.

While the trial did not hit its goals, Intec said data review has shown that certain subsets of patients saw a meaningful reduction in OFF time.

Pumas-AI, a new company established by University of Maryland School of Pharmacy faculty members Vijay Ivaturi, PhD, assistant professor in the Department of Pharmacy Practice and Science, and Joga Gobburu, PhD, MBA, professor in the department, is proud to announce the release of its first, cutting-edge software platform for pharmaceutical researchers and clinicians.

Appointments of Rolf Soderstrom and Dr Jim Esinhart as Non-Executive Directors

Recipharm AB will publish its interim report for January - June 2019 on 25th July at 07:45 am CET.

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced results from their Phase 1 multiple ascending dose study with ACH-5228 outside of the United States.

The drug is approved for use for management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, adjunctive therapy for partial-onset seizures in patients 17 years of age and older, fibromyalgia, and neuropathic pain associated with spinal cord injury.

Takeda will release complete Phase III data at a future scientific conference and is planning on seeking regulatory approval for the investigational formulation.

Revenue and EBITDA for full year 2019 expected to be ahead of market expectations